Compare Kinder Morgan Inc (KMI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Twist Bioscience Corp — how do they compare? Kinder Morgan Inc trades at $31.75 (market cap $70.10B), while Twist Bioscience Corp trades at $121.77 (market cap $7.72B). The key difference: Kinder Morgan Inc is far larger — about 9.1× Twist Bioscience Corp's market cap, and Kinder Morgan Inc pays a 3.75% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| KMI | TWST | |
|---|---|---|
Market Cap | $70.10B | $7.72B |
Sector | Energy | Health |
52-Week High | $34.31 | $124.88 |
52-Week Low | $25.84 | $24.16 |
Enterprise Value | $102.15B | $7.65B |
Dividend Yield | 3.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KMI trades at $31.39, up 1.75% today, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 19.31% net income margin. Recent news highlights a $5 billion Western Gateway Pipeline joint venture with Phillips 66 and HF Sinclair, signaling growth in energy infrastructure.
The outlook is mixed: robust cash flow and dividend sustainability support income investors, but high debt levels and bearish technical indicators pose risks. Analyst consensus is nearly split between Buy and Hold, reflecting cautious optimism amid valuation concerns.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
